Literature DB >> 10438897

Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment.

S A Calarota1, A C Leandersson, G Bratt, J Hinkula, D M Klinman, K J Weinhold, E Sandström, B Wahren.   

Abstract

Intensive chemotherapy is capable of reducing the viral load in HIV-1-infected individuals while infected cells are still present. A special property of DNA immunization is to induce both new CTL and Ab responses. We evaluated the possibility of inducing new immune responses in already infected individuals by means of DNA constructs encoding the nef, rev, or tat regulatory HIV-1 genes. Significant changes in viral loads and CD4+ counts were observed in four patients who started highly active antiretroviral treatment (HAART) during the immunization study. The DNA immunization induced Ag-specific T cell proliferation, which persisted up to 9 mo after the last DNA injection, and cytolytic activities but did not, by itself, reduce viral load. Increased levels of CTL precursor cells were induced in all nine DNA-immunized patients. The profile of IFN-gamma secretion observed when human PBMC were transfected with the nef, rev, and tat DNA resembled that found in the CTL activity (nef > tat > rev). Ab responses that occurred after immunizations were of a low magnitude. In accordance with the high IL-6 production induced by the nef DNA plasmid, IgG titers were highest in patients immunized with nef DNA. The initiation of HAART appears to contribute to the induction of new HIV-specific CTL responses, but by itself did not cause obvious re-induction of these activities.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438897

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.

Authors:  R Wang; J Epstein; F M Baraceros; E J Gorak; Y Charoenvit; D J Carucci; R C Hedstrom; N Rahardjo; T Gay; P Hobart; R Stout; T R Jones; T L Richie; S E Parker; D L Doolan; J Norman; S L Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

Review 2.  Prospects for immune reconstitution in HIV-1 infection.

Authors:  N Imami; F Gotch
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

3.  Vaccination with a codon-optimized A27L-containing plasmid decreases virus replication and dissemination after vaccinia virus challenge.

Authors:  Osmarie Martínez; Ariana Bravo Cruz; Saritza Santos; Maite Ramírez; Eric Miranda; Joanna Shisler; Miguel Otero
Journal:  Vaccine       Date:  2017-06-16       Impact factor: 3.641

4.  Direct ex vivo kinetic and phenotypic analyses of CD8(+) T-cell responses induced by DNA immunization.

Authors:  D E Hassett; M K Slifka; J Zhang; J L Whitton
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 5.  Vaccine development against HIV-1: current perspectives and future directions.

Authors:  Rebecca L Edgeworth; Juan Homero San; Jason A Rosenzweig; Nang L Nguyen; Jean D Boyer; Kenneth E Ugen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

6.  Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques.

Authors:  Amara Luckay; Maninder K Sidhu; Rune Kjeken; Shakuntala Megati; Siew-Yen Chong; Vidia Roopchand; Dorys Garcia-Hand; Rashed Abdullah; Ralph Braun; David C Montefiori; Margherita Rosati; Barbara K Felber; George N Pavlakis; Iacob Mathiesen; Zimra R Israel; John H Eldridge; Michael A Egan
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

7.  GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates.

Authors:  Peter T Loudon; Eric J Yager; Debbie T Lynch; Amithi Narendran; Cristy Stagnar; Anthony M Franchini; James T Fuller; Phil A White; Julia Nyuandi; Clayton A Wiley; Michael Murphey-Corb; Deborah H Fuller
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

8.  A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.

Authors:  S M Agwale; M T Shata; M S Reitz; V S Kalyanaraman; R C Gallo; M Popovic; D M Hone
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-02       Impact factor: 11.205

9.  Modifying the HIV-1 env gp160 gene to improve pDNA vaccine-elicited cell-mediated immune responses.

Authors:  Shakuntala Megati; Dorys Garcia-Hand; Sarah Cappello; Vidia Roopchand; Amjed Masood; Rong Xu; Amara Luckay; Siew-Yen Chong; Margherita Rosati; Solomon Sackitey; David B Weiner; Barbara K Felber; George N Pavlakis; Zimra R Israel; Larry R Smith; John H Eldridge; Maninder K Sidhu; Michael A Egan
Journal:  Vaccine       Date:  2008-04-24       Impact factor: 3.641

10.  Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.

Authors:  Lakshmi Ramakrishna; Krishnamurthy Kumar Anand; Kumarasamypet M Mohankumar; Udaykumar Ranga
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.